Eisai lays out new mid-term plan including job losses
This article was originally published in Scrip
Executive Summary
Eisai has fallen short of the sales target set under its current mid-term business plan, prompting it to bring forward the implementation of a new corporate strategy designed to cope with major patent expiries and to focus more on high-growth emerging markets and therapeutic sectors.